MARKET

PLUR

PLUR

PLURILOCK SEC INC
NASDAQ
5.16
-0.01
-0.19%
Opening 12:40 04/18 EDT
OPEN
5.08
PREV CLOSE
5.17
HIGH
5.19
LOW
5.00
VOLUME
8.80K
TURNOVER
0
52 WEEK HIGH
8.56
52 WEEK LOW
3.449
MARKET CAP
26.97M
P/E (TTM)
-1.0865
1D
5D
1M
3M
1Y
5Y
PLURI INC: ON APRIL 15, GOT LETTER FROM NASDAQ THAT CO HAS REGAINED COMPLIANCE WITH NASDAQ LISTING RULE 5550(A)(2)
Reuters · 1d ago
Weekly Report: what happened at PLUR last week (0408-0412)?
Weekly Report · 3d ago
Pluri stock jumps 9% on US patent for immune cell production
Pluri stock jumps 9% on US patent for immune cell production. Israeli biotech company says the patent will enable mass-scale production of immune cell therapies. Pluri estimates the market will be $11.66B by 2030. The company's stock jumped 9% in morning trading.
Seeking Alpha · 04/08 14:35
Microstrategy, Apartment Income REIT, Marathon Digital among premarket gainers' pack
Microstrategy, Apartment Income REIT, Marathon Digital among premarket gainers' pack. Auddia AUUD +123% on bagging a U.S. Patent for the core AI technology it uses in its radio app. Bitcoin again surpassed the $72,000 level.
Seeking Alpha · 04/08 13:10
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Longeveron (NASDAQ:LGVN) shares moved upwards by 75.0% to $3.85 during Monday's pre-market session. PetVivo Hldgs stock increased by 17.09% and SHL Telemedicine stock moved up by 13.26%. Losers include Supernus Pharmaceuticals and G1 Therapeutics.
Benzinga · 04/08 12:09
Pluri Introduces Groundbreaking Immune Cell Expansion Technology, Secures New US Patent
Pluri Inc. Has been granted a new U.S. Patent for a novel method for expansion of immune cells using proprietary technology. The company's 3D cell expansion technology mimics the natural lymph node like environment that immune cells have in the human body. Pluri's technology represents a paradigm shift in immune cell expansion methodologies.
Benzinga · 04/08 11:07
BREAKTHROUGH IN IMMUNE CELL EXPANSION: PLURI GRANTED U.S PATENT FOR NEW METHOD
Reuters · 04/08 11:01
Weekly Report: what happened at PLUR last week (0401-0405)?
Weekly Report · 04/08 10:59
More
About PLUR
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.

Webull offers Pluri Inc stock information, including NASDAQ: PLUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLUR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLUR stock methods without spending real money on the virtual paper trading platform.